“生血二号”治疗特发性血小板减少性紫癜对巨核细胞影响的实验研究

Impact of ShengxueⅡ on Megalocaryocyte in Mice with Idiopathic Thrombocytopenic Purpura

目的:观察"生血二号"对ITP治疗前后的骨髓巨核细胞的影响。方法:选择血小板减少小鼠共30只,雌雄兼用,分为中药组及激素组,治疗15天后,查骨髓产板巨核细胞数。结果:经小鼠实验表明:中药组和激素组与模型组比较有统计学意义(P<0.01);中药组和激素组与正常组比较无统计学意义(P>0.05);中药组与激素组比较无统计学意义(P>0.05)。结论:"生血二号"能促进巨核细胞向成熟分化,促进血小板生成,说明中药在治疗慢性血小板减少性紫癜较激素安全可靠,疗效显著。

Objective ：To observe the impact of ShengxueⅡ on megalocaryocyte in bone marrow in mice with idiopathic thrombocytope- nic purpura （ITP）. Methods：Thirty male and female mice with thrombocytopenia were treated by Chinese medicine, or by hormone re- spectively for 15 days, and megalocaryocyte in bone marrow were counted. Results：Either the medicine group or hormone group had sig- nificant differences when comparing with the model group （ P 〈 0.01 ） ; but without significant differences when comparing with the nor- mal group （ P 〉 O. 05 ） ; There was no significant different between the medicine group and hormone group （ P 〉 0. 05 ）. Conclusion ： ShengxueⅡ can promote megalocaryocyte differentiation and produce blood platelet, indicating it is a safer and more effective treatment than hormone for the treatment of idiopathic thrombocytopenic purpura.